Lepu ScienTech Revives IPO After Policy Move Brightens Its Prospects

China’s leading supplier of congenital heart disease devices made its third filing earlier this month for a Hong Kong IPO Key Takeaways: After taking its Lepu Biopharma unit public in February, Lepu Medical is pressing ahead with a third attempt at listing is Lepu ScienTech unit in Hong Kong China’s healthcare regulator has said it won’t include innovative medical equipment in its bulk purchase programs, which should help Lepu ScienTech’s profitability Emily Chan Hong Kong’s stock market may be slumping, and the U.S.-China tech war may be spilling over into…

Read More »

Lacking Revenue, Lepu Biopharma Chases IPO to Revive War Chest

The cutting-edge cancer treatment company has not generated any revenue from its products, and only has enough money to last another three months Key takeaways: Lepu Biopharma has yet to generate product-related revenue, and with only $41 million in cash is desperate for a quick capital injection through an IPO Cancer treatment specialist has sold out international portion of its share quota, but domestic portion has met with lukewarm reception By Fai Pui Their names may be unfamiliar to most, but PD-1 inhibitors, “smart missile” ADCs and oncolytic viruses (OV)…

Read More »

PW Medtech’s Buying Spree: Diversification or Insider Story?

The manufacturer of medical infusion devices has recently made two interesting acquisitions Key takeaways: After buying a related peer in November, PW Medtech acquired a human tissue regeneration and repair product developer last week at a high premium The company’s performance has been affected by the pandemic, and it may hope the new acquisitions will lower such risk through diversification By Jony Ho Medical device maker PW Medtech Group Ltd. (1358.HK) has struggled lately, dragged down by pandemic-related disruptions. Perhaps seeking to lower that risk, the company has made two…

Read More »